Catalyst Wire Dossier Catalyst Wire Dossier

Quizartinib (AC220)

quizartinib · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Quizartinib (AC220), covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) [Phase 2]

See pricing